Rhenman & Partners Asset Management Ab Adverum Biotechnologies, Inc. Transaction History

Rhenman & Partners Asset Management Ab

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$3.36 - $10.56 $2.18 Million - $6.86 Million	-650,000 Closed	0 $0
Q1 2021 May 14, 2021	BUY	$9.26 - $14.36 $231,500 - $359,000	25,000 Added 4.0%	650,000 $6.41 Million
Q3 2020 Oct 13, 2020	BUY	$10.3 - $21.64 $1.29 Million - $2.71 Million	125,000 Added 25.0%	625,000 $6.44 Million
Q2 2020 Jul 16, 2020	SELL	$8.53 - $25.64 $426,499 - $1.28 Million	-50,000 Reduced 9.09%	500,000 $10.4 Million
Q1 2020 Apr 16, 2020	SELL	$7.98 - $16.32 $798,000 - $1.63 Million	-100,000 Reduced 15.38%	550,000 $5.37 Million

Q4 2019 Jan 17, 2020	BUY	$5.12 - $12.22 $2.72 Million - $6.48 Million	530,327 Added 443.15%	650,000 $7.49 Million
Q4 2018 Feb 05, 2019	SELL	$2.87 - $5.92 $98,418 - $203,008	-34,292 Reduced 22.27%	119,673 $377,000
Q2 2018 Jul 20, 2018	BUY	$5.3 - $6.9 $142,882 - $186,017	26,959 Added 21.23%	153,965 $816,000
Q4 2017 Jan 19, 2018	SELL	$2.85 - $3.95 $76,950 - $106,650	-27,000 Reduced 17.53%	127,006 $445,000
Q3 2017 Oct 13, 2017	BUY	$2.45 - $3.65 $377,314 - $562,121	154,006	154,006 $562,000

3.6M

Ticker ADVM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,333,600
Market Cap $679M
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration an...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.